SmallCapReview.com a leading site for news and information on small caps, penny stocks and microcaps is adding Spectrum Pharmaceuticals (Nasdaq: SPPI) and FX Energy (Nasdaq: FXEN) to its list of stocks "On the Radar".
Spectrum Pharmaceuticals (SPPI) is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology. The Company’s strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products.
The Company markets two oncology drugs, FUSILEV and ZEVALIN and has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of novel drug candidates.
The Company has assembled an integrated in-house scientific team, including clinical development, medical research, regulatory affairs, biostatistics and data management, formulation development, and has established a commercial infrastructure for the marketing of its drug products. SPPI also leverages the expertise of its worldwide partners to assist in the execution of its strategy.
Announced that updated data from the ZEVALIN injection for intravenous use Phase 3 First-line Indolent Trial showed a nearly three-year advantage in median progression-free survival compared to patients treated with either chemotherapy alone or chemotherapy plus rituximab (49 months versus 14 months).
Spectrum Pharmaceuticals plans to submit data for consideration to the U.S. Food and Drug Administration to remove the bioscan requirement prior to ZEVALIN administration. Spectrum believes removal of the requirement will further improve the convenience of ZEVALIN administration and thereby further facilitate its adoption as the standard of care in first-line consolidation setting for follicular non-Hodgkin’s lymphoma.
Announced independent researchers from leading universities in Germany, Austria, Italy, and Sweden, reported early positive results from the first Phase 2 clinical trial evaluating treatment-naïve patients with follicular non-Hodgkin’s lymphoma (NHL) treated with ZEVALIN injection for intravenous use as a monotherapy.
Announced that the FDA has accepted for filing and review the complete response regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.
--------
FX Energy (FXEN) is an independent oil and gas exploration and production company with production in the US and Poland. The Company's main exploration and production activity is focused on Poland's Permian Basin where the gas-bearing Rotliegend sandstone is a direct analog to the Southern Gas Basin offshore England.
FXEN holds interests in 9 project areas encompassing approximately 4.7 million gross acres in Poland. It also explores for and produces oil from fields in Montana and Nevada, the United States; and holds interests in an oilfield services company that offers contract drilling and well-servicing operations in northern Montana.
FXEN Investor Highlights
Announced net income of $22.2 million, or $0.51 per share, for the quarter ended September 30, 2010.
Higher third quarter production was the largest contributor to the Company's improved quarter results. Total net oil and gas production almost doubled to 889 million cubic feet equivalent (Mmcfe) during the third quarter of 2010, compared to 472 Mmcfe during the 2009 quarter.
Announced that the Company will begin a new 2D seismic acquisition program during the fourth quarter 2010. The program is planned to identify drill sites in the Company's 640,000 acre Warsaw South concession. A total of 273 kilometers of seismic will be acquired under a recently signed contract with Geofizyka Torun.
Announced the signing of a definitive Joint Operating Agreement with the Polish Oil and Gas Company covering operations in the Company's 710,000 acre Kutno concession block in central Poland. POGC will earn a 50% interest in the block in connection with drilling of the first well; FX will be the operator.
The prospect is believed to be the largest undrilled Rotliegend structure on-shore Europe. Well design and engineering are currently underway with drilling planned in 2011.
Reported that the Lisewo well has started drilling on FX Energy's 850,000 acre Fences concession in western Poland. FX Energy owns 49% of the Lisewo well. The Polish Oil and Gas Company is the operator and owns 51%.
To learn more about SPPI and FXEN visit www.smallcapreview.com
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview.com has not been compensated for its efforts with regards to Spectrum Pharmaceuticals or FX Energy, nor does it hold any positions at this time.
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers.
